Humanized Anti-CD22 Recombinant Antibody (clone Pinatuzumab) (CAT#: TAB-899)

This product is a humanized (from mouse) IgG1, κ antibody that can recognize human CD22.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Incidence of >10% of all treatment-emergent AEs in patients receiving single-agent pinatuzumab vedotin (2.4 mg/kg): iNHL versus DLBCL.

Figure 1 Incidence of >10% of all treatment-emergent AEs in patients receiving single-agent pinatuzumab vedotin (2.4 mg/kg): iNHL versus DLBCL.

Most AEs reported in the 39 NHL patients treated at the RP2D (2.4 mg/kg) were grade 1–2 in severity. Twenty-seven (69%) patients reported grade 3–4 adverse events; the most common in ≥2 patients included neutropenia, fatigue, peripheral sensory neuropathy, hyperglycemia, and anemia. Grade 3 febrile neutropenia was reported in one patient. Serious AEs were reported in 13 (33%) NHL patients. Pyrexia was reported in 3 patients and dyspnea in 2 patients; otherwise, no single serious AE was reported in ≥2 patients. Thirteen (33%) patients discontinued pinatuzumab vedotin treatment due to an AE.

Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., ... & Agarwal, P. (2017). Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 23(5), 1167-1176.

Figure 2 Tumor reductions were mostly observed at pinatuzumab vedotin doses ≥1.8 mg/kg.

Figure 2 Tumor reductions were mostly observed at pinatuzumab vedotin doses ≥1.8 mg/kg.

Observed antitumor responses in DLBCL patients (A) and iNHL patients (B). Dashed lines indicate 50% increases and 50% decreases in SPD from baseline. R, refractory; SPD, sum of the product of the diameters.

Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., ... & Agarwal, P. (2017). Phase I study of the anti-CD22 antibody–drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research, 23(5), 1167-1176.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Humanized (from mouse)
  • Type
  • Humanized (from mouse) IgG1, κ
  • Specificity
  • Human CD22
  • Species Reactivity
  • Human
  • Clone
  • Pinatuzumab
  • Applications
  • FC, IP, ELISA, Neut, FuncS, IF, ICC

Product Property

  • Purification
  • Protein A/G Purified
  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • This antibody has been reported for use in Flow Cytometry, Immunoprecipitation, Enzyme-linked Immunosorbent Assay, Neutralization, Functional Assay, Immunofluorescence, Immunocytochemistry.

Target

  • Alternative Names
  • SIGLEC2; SIGLEC-2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; sialic acid-binding Ig-like lectin 2

Related Resources

  • Biosimilar Overview
Please refer to Pinatuzumab Vedotin Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Pinatuzumab Vedotin.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone Pinatuzumab"

See other products for "CD22"

Select a product category from the dropdown menu below to view related products.
Please select product type
scFv Fragment Antibody Mouse Antibody Immunotoxin Chimeric Antibody Human Antibody Humanized Antibody Fab Glycosylation Fc Glycosylation Blocking Antibody Rabbit Monoclonal Antibody Recombinant Antibody Fab Fragment Antibody ADCC Enhanced Antibody

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-899. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare